Nuvalent: Two Near-Term Shots On Goal Make a High-Reward Long Trade
Nuvalent is a clinical-stage precision oncology company with two lead kinase programs that have near-term regulatory and pivotal catalysts in 2026. The stock trades at about $99.35 with a market cap near $7.85B and roughly $2.87B in cash on the balance sheet. This trade idea is a directional long into upcoming FDA decisions and program readouts, wi…